Real-world Treatment Patterns and Clinical Outcomes Associated With Palbociclib Combination Therapy: A Multinational, Pooled Analysis From the Ibrance Real World Insights Study

Sung, 2021, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA Cancer J. Clin, 71, 209, 10.3322/caac.21660 2021 2019 2021 Cardoso, 2020, 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5), Ann Oncol, 31, 1623, 10.1016/j.annonc.2020.09.010 Ballinger, 2018, Current landscape of targeted therapies for hormone-receptor positive, HER2 negative metastatic breast cancer, Frontiers Oncol, 8, 308, 10.3389/fonc.2018.00308 Waller, 2019, Real-world treatment patterns and clinical outcomes in patients receiving palbociclib for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in Argentina: The IRIS study, J Glob Oncol, 5 Mycock, 2021, Real-world palbociclib use in HR+/HER2- advanced breast cancer in Canada: The IRIS study, Curr. Oncol, 28, 678, 10.3390/curroncol28010066 Taylor-Stokes, 2019, Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study, Breast, 43, 22, 10.1016/j.breast.2018.10.009 Finn, 2016, Palbociclib and letrozole in advanced breast cancer, N Engl J Med, 375, 1925, 10.1056/NEJMoa1607303 Cristofanilli, 2016, Lancet Oncol, 17, 425, 10.1016/S1470-2045(15)00613-0 De Laurentiis, 2020, Abstract P3-11-25: Real-world treatment patterns and clinical outcomes among women with HR+/HER2- advanced or metastatic breast cancer treated in real-world settings in Italy and Germany, Cancer Res, 80, 10.1158/1538-7445.SABCS19-P3-11-25 DeMichele, 2021, Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice, Breast Cancer Res, 23, 37, 10.1186/s13058-021-01409-8 Kouzy, 2020, Performance status restriction in phase III cancer clinical trials, J. Clin. Oncol, 38, 2059, 10.1200/JCO.2020.38.15_suppl.2059 Keim-Malpass, 2021, Association of age at cancer diagnosis and clinical trial participation, JAMA Network Open, 4, 10.1001/jamanetworkopen.2020.37573 Lee, 2021, Real-world clinical data of palbociclib in Asian metastatic breast cancer patients: Experiences from eight institutions, Cancer Res. Treat, 53, 409, 10.4143/crt.2020.451